Laforest H, Taurelle R
Service de Gynécologie-Obstétrique, Hôpital Boucicaut, Paris.
Rev Fr Gynecol Obstet. 1994 Apr;89(4):181-91.
While the value of hormone replacement therapy appears now to be accepted, it is above all a prophylactic technique requiring evaluation of its benefit/risk ratio. The possible increased risk of breast cancer linked to this type of treatment remains a preoccupation which probably limits its more widespread use. The natural history of this cancer and inherent biases in the various types of study are such that analysis of the literature is often difficult and any definite conclusion is prevented. Certain trends nevertheless appear to emerge from the principal studies. While there is indeed an increased risk of onset of breast cancer, it is slight, other than with the use of high doses of estrogens for prolonged periods in women with a family history of breast cancer. Decreased overall mortality rate in women on replacement therapy and the improvement in their comfort tend to suggest that it is now legitimate to offer such treatment, provided its contra-indications are strictly observed and regular monitoring is ensured.
虽然激素替代疗法的价值如今似乎已被认可,但它首先是一种预防性技术,需要评估其效益/风险比。与这种治疗方式相关的乳腺癌风险可能增加,这仍是一个令人担忧的问题,可能限制了它更广泛的应用。这种癌症的自然病史以及各类研究中固有的偏差使得文献分析往往困难重重,难以得出任何明确结论。然而,主要研究中似乎确实出现了某些趋势。虽然乳腺癌发病风险确实有所增加,但这种增加很轻微,不过在有乳腺癌家族史的女性中长期使用高剂量雌激素的情况除外。接受替代疗法的女性总体死亡率降低以及舒适度提高,这往往表明,只要严格遵守其禁忌症并确保定期监测,现在提供这种治疗是合理的。